Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage EFLK1
- Development stage
- Preclinical
- Lead developer
- Hebrew University of Jerusalem
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical, Intraperitoneal
01
Overview
Bacteriophage EFLK1 is a lytic bacteriophage belonging to the *Spounavirinae* subfamily of the *Myoviridae* (or *Herelleviridae*) family. It was isolated from sewage effluents by researchers at the Hebrew University of Jerusalem to target vancomycin-resistant *Enterococcus faecalis* (VRE), particularly strains that had developed resistance to another lytic phage, EFDG1. EFLK1 has demonstrated potent lytic activity against both planktonic and biofilm-embedded *E. faecalis* in vitro and in vivo, including models of prosthetic valve endocarditis (PVE) and root canal infections. It is often studied alone, in combination with antibiotics (such as vancomycin or ceftriaxone), or as part of a phage cocktail with EFDG1 to prevent the emergence of phage-resistant bacterial mutants.
- Other names
- EFLK1EFLK-1EFLK 1Enterococcus bacteriophage EFLK1Enterococcus phage EFLK1
Beyond the preview
Go deeper on bacteriophage EFLK1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage EFLK1.